Tectonic Therapeutic, Inc. (TECX)
- Previous Close
20.99 - Open
21.21 - Bid 23.17 x 100
- Ask 23.58 x 100
- Day's Range
20.68 - 23.60 - 52 Week Range
1.40 - 61.07 - Volume
345,036 - Avg. Volume
228,127 - Market Cap (intraday)
437.123M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-3.14 - Earnings Date Aug 12, 2025 - Aug 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
82.75
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
tectonictx.comRecent News: TECX
View MorePerformance Overview: TECX
Trailing total returns as of 5/19/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TECX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TECX
View MoreValuation Measures
Market Cap
437.12M
Enterprise Value
133.51M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.45
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.89%
Return on Equity (ttm)
-41.60%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-58.67M
Diluted EPS (ttm)
-3.14
Balance Sheet and Cash Flow
Total Cash (mrq)
141.24M
Total Debt/Equity (mrq)
2.35%
Levered Free Cash Flow (ttm)
-71.34M